The prevalence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections is increasing globally and in Singapore. Skin and soft tissue infections (SSTIs) are the most common manifestations, ranging from common furuncles to the rare but life-threatening necrotizing fasciitis. Surgical drainage and debridement where feasible are the mainstay of therapy, whereas MRSA-active antibiotics are essential when surgery is not possible or as adjunctive therapy for severe and/or complicated SSTIs. In itself, the continued inexorable rise in CA-MRSA rates poses difficult challenges for primary healthcare and hospital infection control. Innovative approaches are required to mitigate its impact in both the community and hospital settings.
InTroduCTIon
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has become an increasingly recognized cause of infection in both children and adults globally. Unlike the "older" healthcare-associated MRSA (HA-MRSA), CA-MRSA strains can cause infections in healthy individuals and disseminate successfully outside institutional healthcare settings, signifying the latest (but definitely not last) evolutionary leap in terms of fitness and virulence of the remarkably adaptive organism that is S. aureus 1 .
The first part of this article describes the basis for methicillin resistance and current postulates for the rise in CA-MRSA, whereas the second part focuses on the epidemiological and clinical issues involving CA-MRSA, in particular on the management and prevention of skin/soft tissue (SSTI) infections.
Methicillin resistance
The discovery of transmissible S. aureus isolates that were resistant to methicillin occurred in 1961 -two years after widespread clinical use of that antibiotic 2 . But it was not until 1985 that Utsui and Yokota described the altered penicillin-binding protein (PBP2a) that forms the predominant mechanism of resistance of MRSA to virtually all β-lactam antibiotics 3 . PBP2a has several thousand-fold less affinity than other staphylococcal penicillin-binding proteins for β-lactam antibiotics and is encoded by the mecA gene, which is embedded in various mobile genetic elements collectively termed the staphylococcal cassette chromosome mec (SCCmec) 4 . Other staphylococcal mechanisms of resistance to methicillin exist, including β-lactamase hyperproduction, but these are comparatively rare and will not be further discussed.
It has been known for some time that SCCmec are not native to S. aureus. They are horizontally distributed among a wide variety of other Staphylococcus spp., and their origin remains shrouded in mystery 5 . Besides the mecA gene, the other major components of SCCmec include the chromosome cassette recombinase (ccr) genes that render these elements mobile, as they encode Proceedings of Singapore Healthcare  Volume 19  Number 3  2010 for proteins enabling integration into and excision from the attBscc site of the S. aureus chromosome 4, 5 . There are at least eight SCCmec types in existence, of which SCCmec I-III and VIII are found predominantly in healthcare-associated MRSA (HA-MRSA), V-VII exclusively in CA-MRSA, and SCCmec IV in both 4, 5 .
The use of an internationally standardized molecular typing method -multilocus sequence typing (MLST) -has led to the discovery that methicillin resistance is present only within a narrow range of S. aureus clonal complexes 6 . It appears that not all S. aureus clones can become MRSA despite the availability of SCCmec, and this selection is regulated by as yet undetermined elements within the S. aureus chromosome 7, 8 .
Healthcare-vs. Community-Associated MrSA
Published reports of MRSA between 1961 and 1990 showed that it was found almost exclusively in healthcare-associated settings 9 , and it was not until the early 1990's that MRSA infections were described in patients without any healthcareassociated risk factors 10, 11 . Even then, many experts initially believed that these isolates were merely feral strains of HA-MRSA that had somehow survived to circulate in the community 12 . With careful epidemiological investigation and the use of newer molecular typing methods, however, investigators had clearly shown by the earlier part of this decade that CA-MRSA strains were unrelated to their healthcare-associated counterparts, affected a disparate profile of patients, and caused a different spectrum of infections -predominantly skin and soft tissue infections 1, 4, [13] [14] .
The question of why HA-MRSA had generally failed to disseminate beyond healthcare-related boundaries is worth addressing, as it also explains in part the success of CA-MRSA as a community pathogen. The present best hypothesis is that the presence of the older and larger SCCmec types I-III resulted in fitness costs to the organism, rendering it less competitive than methicillin-susceptible S. aureus (MSSA) in environments where the antibiotic selection pressure is lower and transmissibility barriers are higher (i.e. most non-healthcare associated settings). Okuma and co-workers demonstrated that HA-MRSA had slower growth rates compared to MSSA in vitro 4 , while Ender and co-workers showed heightened metabolic activity correlating with mecA expression in MSSA transfected with SCCmec I -the first SCCmec type identified in HA-MRSA [15] . CA-MRSA on the other hand appears to have overcome these obstacles: the later SCCmec types (IV-VII) are much smaller and comparatively more compact 5 , and do not appear to confer fitness costs in terms of a slower growth rate 4 or increased metabolic requirements 16 . Thus CA-MRSA strains are able to compete successfully against MSSA in the community setting.
The converse question is whether CA-MRSA will replace HA-MRSA in the healthcare setting. HA-MRSA strains tend to be resistant to more classes of antibiotics compared to CA-MRSA or MSSA in general 1, 4, 9 , and this undoubtedly contributes to their ongoing success in the healthcare setting. The optimum antibiotic resistance phenotype is unknown and is possibly in a state of flux depending on the antibiotics prescribed in each hospital over time -in recent years, less multiply-resistant HA-MRSA have started to replace older and more resistant clones worldwide 17, 18 . In any case, CA-MRSA may also acquire more antibiotic resistance determinants, and "multidrugresistant" CA-MRSA have successfully replaced HA-MRSA in isolated parts of the US and Taiwan where the prevalence of CA-MRSA is high [19] [20] [21] . From an evolutionary standpoint then, the question is "when" rather than "if" CA-MRSA will eventually replace HA-MRSA in the healthcare setting.
Panton-Valentine Leukocidin
Panton-Valentine leukocidin (PVL) is a bicomponent S. aureus-specific exotoxin that is associated with skin/soft tissue furuncles and abscesses as well as necrotizing pneumonia 13, 22, 23 . It is directly dermonecrotic on both intact and damaged skin, but its impact on leukocytes and macrophages result in the clinical manifestations observed 23 . In these cells, PVL induces cell lysis or apoptosis (depending on the concentration of the toxin) via non-specific pore formation with subsequent release of intracellular enzymes 23 .
Vandenesch and co-workers first identified PVL as a putative stable genetic marker for CA-MRSA 13 , but its exact ecological role in CA-MRSA is poorly understood at present. It should be noted that not all CA-MRSA strains carry the PVL genes 24, 25 , and it is therefore unreliable if used alone as a molecular identifier for CA-MRSA.
Review
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Prevalence of CA-MrSA infection and colonization
The global distribution of CA-MRSA has been extensively described in two recent review articles and therefore will not be further discussed here 9, 26 .
Locally, the first reported CA-MRSA infection dates back to 2001 -an Indian diabetic male with necrotizing pneumonia -and the majority of initial CA-MRSA isolates were imported 27 . Since then, however, non-systematic data collection has revealed that the number of infections have increased progressively ( Fig. 1) , with the emergence of a predominant ST30-IVc clone, suggesting local transmission [28] [29] . Brief epidemiological investigation did not unearth any link between the patients with clonal CA-MRSA infections, although it was noted that a higher than expected proportion of cases -14.3% -occurred among Filipino expatriates (both maids, nurses, and construction workers) 29 . This unexpected observation was again repeated in Hong Kong 30 and Denmark 31 over the past few years.
No epidemiological survey has been conducted to date to determine the prevalence of carriage of CA-MRSA in Singapore CA-MrSA Infections CA-MRSA most frequently presents as SSTIs. The predilection for SSTI has been postulated to be due to the presence of PVL as discussed above. SSTIs are typically impetigo, furuncles (boils), pimples or abscesses in otherwise healthy individuals 1, 11, 30 . However, it can also cause severe invasive infections ranging from pyomyositis, osteomyelitis and necrotizing fasciitis to necrotizing pneumonia and septicemia [19] [20] [21] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Infections can rarely progress rapidly from SSTI to invasive infection with multiorgan failure and death 36, 37 .
Approximately 50% of affected patients present with cutaneous abscesses whereas 30% present with cellulitis 38, 39 . Abscesses may not be associated with fever or raised inflammatory markers. Furuncles are fairly common especially in outbreaks 31, 40 , although this phenomenon may well be because patients with furuncles are less likely to seek formal medical attention. These furuncles are typically necrotic due to tissue destruction and can progress to develop abscesses and cellulitis 23 . Impetigo is more common in children 38 , as is staphylococcal scalded skin syndrome.
Cases of necrotizing fasciitis due to CA-MRSA have also been reported, with large case series from northern Taiwan and San Francisco, USA 32, 33 . While many of these individuals had co-morbidities such as hepatitis C, diabetes mellitus, and/or previous or current intravenous drug use, there were also others in both series that did not have any pre-existing medical conditions 32, 33 . Myositis and pyomyositis due to CA-MRSA has been more commonly reported in children, with a tendency to occur in the muscles of the thigh and pelvis 34, 35 . These infections required more extensive surgical intervention compared to pyomyositis caused by MSSA 35 .
Transmission of CA-MrSA
Investigations of outbreaks associated with CA-MRSA have suggested that there are certain common risk factors for transmission. Close contact with an infected or colonized individual has been integral to outbreaks of CA-MRSA. Transmission is enhanced in the presence of skin cuts and trauma as well as the sharing of potentially contaminated personal items such as towels, razors and sporting equipment 41, 42 . Outbreaks have been reported in newborns, healthy adults, pregnant women, soldiers and prisoners [43] [44] [45] [46] [47] . As might be expected, transmission has also occurred through activities in which direct contact and abrasion are common -outbreaks of infections have thus been seen among participants in American football, wrestling and fencing [48] [49] [50] [51] [52] . The nature of these sports, with considerable physical contact, abrasions and sharing of equipment, has resulted in the amplification of transmission in many instances.
diagnosis
Other than outbreak-related cases, diagnosing a CA-MRSA infection is possible only when culture-positive clinical specimens are obtained from an individual who presents with SSTI or other infections. It is not possible to differentiate between CA-MRSA and other pathogens (such as MSSA, HA-MRSA or streptococci) based on clinical characteristics and epidemiology alone. The Centers for Disease Control and Prevention (US CDC) has put up epidemiological criteria for differentiating CA-from HA-MRSA [53] . As discussed above, these criteria (along with others such as antibiotic resistance phenotype or PVL detection when used individually) will underestimate the true prevalence of CA-MRSA, particularly in areas where CA-MRSA rates are already high. Ultimately, a combination of molecular typing methods including PVL detection, SCCmec typing, and MLST is required to conclusively differentiate CA-from HA-MRSA.
Therapy
The mainstay of therapy for furuncles, abscesses and severe SSTIs caused by CA-MRSA is surgical drainage or debridement followed by treatment with an appropriate antibiotic -if clinically indicated -based on the susceptibility profile of the organism 41, 54 . Surgical debridement and/or drainage alone may be curative for a significant proportion of patients [54] [55] [56] . There are no prospective randomized studies on this issue, although higher odds of treatment failure (64.4% vs. 39.1%; OR:2.82, 95%CI:1.49-5.34) were found in one retrospective study in surgically treated patients with SSTI who had not received concurrent antibiotics active against CA-MRSA 54 .
Clinical judgment should be used to determine if antibiotics are necessary. Effective antibacterial therapy may be essential for those with cellulitis, small abscesses that cannot be drained, and severe infections such as necrotizing fasciitis. Although CA-MRSA tends to be more susceptible than HA-MRSA to non-beta-lactam antibiotics such as macrolides, clindamycin, doxycycline, trimethoprimsulfamethoxazole and fluoroquinolones, these susceptibility profiles are not predictable and clinical specimens should be obtained with susceptibility testing performed to guide treatment.
One well-known caveat pertains to the concept of inducible clindamycin resistance (inducible macrolide-lincosamide-streptogramin B resistance). Although clindamycin is a good treatment option for CA-MRSA SSTIs, isolates that are resistant to erythromycin may have inducible or constitutive cross-resistance to clindamycin because of the presence of erm genes 57 . Therapeutic failure may develop with clindamycin use, particularly if a macrolide had been prescribed beforehand.
Vancomycin has remained the cornerstone of treatment for MRSA infections. However, recent concerns have centered on the vancomycin minimum inhibitory concentration (MIC) "creep" -where it was noticed at several sites that the vancomycin MIC for MRSA had increased gradually over the past two decades 58,59 -as well as higher therapeutic failure rates encountered when the vancomycin MIC had exceeded 1.0 µg/ml 60, 61 . Vancomycin resistance or heteroresistance has Review Proceedings of Singapore Healthcare  Volume 19  Number 3  2010 not been described in CA-MRSA. Despite these concerns, it should be noted that no clinical trial to date has demonstrated the superiority of any antibiotic when compared to vancomycin for the treatment of SSTIs [62] [63] [64] [65] [66] . Therapeutic success rates have been uniformly high, denoting the importance of surgery in the management of such infections.
Other novel antimicrobial drug classes with activity against MRSA include oxazolidinones, lipopeptides, glycylcyclines, and anti-MRSA beta-lactams. Linezolid, an oxazolidinone with bacteriostatic activity has the added advantage that it can be given orally as well as intravenously. Linezolid is non-inferior to vancomycin for the treatment of complicated SSTI and is associated with shorter hospitalization 62, 63 . Daptomycin is a cyclic lipopeptide that is bactericidal to Grampositive bacteria including MRSA. It is available only in an intravenous formulation and has comparable cure rates when compared with vancomycin for the treatment of SSTIs 64 . Tigecycline is a glycylcycline that acts on the inhibition of ribosomal protein synthesis. It has a broader spectrum of antibacterial activity and studies in SSTIs infections found comparable cure rates when compared with vancomycin-aztreonam 65 . Ceftobiprole and ceftaroline are anti-MRSA betalactams that have high binding affinity for PBP2aboth have demonstrated comparable efficacy with vancomycin for SSTIs 66, 67 . The last two drugs are currently not available for use in Singapore.
Prompt treatment of complicated SSTIs caused by CA-MRSA increases the chances of better outcomes. Cellulitis may be treated with oral antibiotics such as trimethoprim-sulfamethoxazole or clindamycin, and abscesses that are adequately drained may not require concomitant antibiotics. Adjunct antibiotics are useful in complicated and severe SSTIs -vancomycin or any of the newer agents listed above are equivalent in terms of clinical efficacy. Death due to SSTIs is uncommon but recurrence of infection is frequent due to CA-MRSA colonization. Decolonization with mupirocin and chlorhexidine may prevent recurrence of infection and transmission to close contacts 31 .
Public/primary health issues
The high prevalence of CA-MRSA in parts of the US and Taiwan may well foreshadow events locally and globally [19] [20] [21] [40] [41] [42] . Their experience is therefore invaluable in preparing for such an eventuality.
But prior to this, one might well ask if this is truly inevitable or can the CA-MRSA phenomenon be reversed? Denmark had reported success in reducing the rates of ST30-IVc CA-MRSA via adapting their "search and destroy" hospital MRSA policy to the community 31 . However, it is difficult to even contemplate implementing this in cosmopolitan crowded cities like Singapore. Some experts have advised better human and animal antimicrobial prescription controls 68, 69 , but these recommendations are nebulous and their efficacy is doubtful. In our opinion, innovative approaches are required that will either minimize the impact of S. aureus and therefore CA-MRSA infections (e.g. an effective vaccine) or reduce the transmissibility of the organism (e.g. vaccine or hygiene/social innovations). Short of these paradigm shifts occurring, it remains worthwhile to monitor CA-MRSA prevalence trends even though this is far more costly (in view of the molecular typing and epidemiological data collection required) compared to monitoring HA-MRSA trends. As CA-MRSA rates increase, treatment protocols for community SSTIs will have to change to reflect a reduced role for empirical beta-lactam antibiotics such as cloxacillin or amoxicillin/ clavulanate. Hospital infection control practices will have to adapt to the changing situation as well.
Current local hospital infection control practices are poorly suited to address a rising MRSA prevalence from the community. The actual clinical impact of CA-MRSA clones replacing HA-MRSA clones within hospitals -as discussed above -is likely to be imperceptible: current CA-MRSA nosocomial infections do not present differently from HA-MRSA infections, nor are patient outcomes worse (or better) [19] [20] [21] . Fears that the heightened transmissibility of CA-MRSA may diminish the success of hospital infection control interventions are theoretical at present. However, an increasing influx of CA-MRSA cases will strain current isolation and cohort resources in local hospitals. Contemporary local MRSA active surveillance interventions are directed towards patients with healthcare-associated risk factors, and will therefore miss CA-MRSA cases. Increasing active surveillance activity to include all newly admitted patients is prohibitive in terms of costs/resources and may not be cost-effective if isolation or cohort resources are unavailable. At some point in time over the next decade, given current global CA-MRSA prevalence trends, it is likely that hospitals and health authorities will have to decide whether to expend more resources to maintain current gains from the reduction of HA-MRSA rates, or focus on more general hygiene and infection control practices (effectively giving up a more directed approach against MRSA). This is not a true dichotomy of choices, of course -calibrated approaches over time given different prevalence rates of HA-and CA-MRSA are more likely to be successful albeit difficult to implement.
ConCLuSIon
It is clear that the phenomenon of CA-MRSA represents a successful evolutionary leap by S. aureus. It is thus likely that CA-MRSA rates will continue to increase both locally and internationally, perhaps analogous to the spread of penicillin resistance among S. aureus decades ago [70] . The present prevalence of CA-MRSA in Singapore is low; consequently, there is time to formulate strategies that will mitigate its growing impact in the future. Besides developing treatment guidelines for CA-MRSA SSTIs and other infections, and monitoring of CA-MRSA trends (including molecular typing), consideration should be given towards innovative infection control measures and approaches for dealing with CA-MRSA in the future.
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